Modality
Peptide
MOA
HER2
Target
PD-L1
Pathway
Checkpoint
Huntington'sDMDFSGS
Development Pipeline
Preclinical
Jan 2020
→ Aug 2028
PreclinicalCurrent
NCT06327591
2,503 pts·Huntington's
2020-07→2028-05·Recruiting
NCT04667643
1,812 pts·DMD
2020-01→2028-08·Not yet recruiting
4,315 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-052.1y awayInterim· Huntington's
2028-08-132.4y awayInterim· DMD
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2028-05-05 · 2.1y away
Huntington's
Interim
2028-08-13 · 2.4y away
DMD
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06327591 | Preclinical | Huntington's | Recruiting | 2503 | PANSS |
| NCT04667643 | Preclinical | DMD | Not yet recr... | 1812 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |